Skip to main content

Table 2 Main results of pooled ORs and stratification analysis of IRF4 polymorphisms on cancer risk in the meta-analysis

From: Association of interferon regulatory factor 4 gene polymorphisms rs12203592 and rs872071 with skin cancer and haematological malignancies susceptibility: a meta-analysis of 19 case–control studies

rs12203592

TT vs CC

CT vs CC

Dominant model

Recessive model

Additive model

C/T

OR

95% CI

Pa

OR

95% CI

Pa

OR

95% CI

Pa

OR

95% CI

Pa

OR

95% CI

Pa

Overall

1.566

(1.087,2.256)*

0.000

1.070

(0.904,1.266)*

0.000

1.135

(0.941,1.368)*

0.000

1.526

(1.107,2.104)*

0.001

1.168

(0.981,1.392)*

0.000

Source of controls

PB

0.933

(0.672,1.295)

0.403

0.904

(0.793,1.031)

0.320

0.907

(0.799,1.029)

0.265

0.971

(0.701,1.345)

0.420

0.926

(0.830,1.033)

0.215

HB

2.094

(1.314,3.336)*

0.000

1.203

(0.936,1.547)*

0.000

1.314

(1.002,1.723)*

0.000

1.959

(1.310,2.931)*

0.003

1.351

(1.058,1.725)*

0.000

Cancer type

Skin cancer

1.808

(1.127,2.900)*

0.000

1.130

(0.890,1.435)*

0.000

1.217

(0.935,1.584)*

0.000

1.728

(1.145,2.608)*

0.000

1.253

(0.983,1.596)*

0.000

Melanoma

1.315

(0.624,2.770)*

0.000

0.957

(0.724,1.265)*

0.009

1.011

(0.715,1.431)*

0.000

1.321

(0.684,2.552)*

0.001

1.057

(0.747,1.497)*

0.000

BCC

2.511

(1.630,3.867)

0.430

1.085

(0.861,1.368)

0.668

1.245

(1.004,1.543)

0.996

2.451

(1.600,3.755)

0.383

1.352

(1.131,1.617)

0.644

SCC

2.520

(1.598,3.974)

0.703

1.651

(1.330,2.049)

0.208

1.743

(1.418,2.143)

0.207

2.120

(1.354,3.318)

0.901

1.643

(1.385,1.949)

0.303

NHL

1.074

(0.734,1.571)

0.677

0.948

(0.820,1.096)

0.545

0.960

(0.834,1.104)

0.734

1.103

(0.756,1.608)

0.589

0.979

(0.867,1.106)

0.914

Ethnicity

Caucasian

1.808

(1.127,2.900)*

0.000

1.130

(0.890,1.435)*

0.000

1.135

(0.941,1.368)*

0.000

1.728

(1.145,2.608)*

0.000

1.253

(0.983,1.596)*

0.000

Mixed

1.074

(0.734,1.571)

0.677

0.948

(0.820,1.096)

0.545

0.960

(0.834,1.104)

0.734

1.103

(0.756,1.608)

0.589

0.979

(0.867,1.106)

0.914

rs872071

GG vs AA

GA vs AA

Dominant model

Recessive model

Additive model

G/A

OR

95% CI

P a

OR

95% CI

P a

OR

95% CI

P a

OR

95% CI

P a

OR

95% CI

P a

Overall

1.805

(1.402,2.323)*

0.002

1.427

(1.203,1.692)*

0.034

1.556

(1.281,1.891)*

0.003

1.432

(1.293,1.587)

0.109

1.349

(1.201,1.515)*

0.002

Source of controls

PB

1.767

(1.244,2.511)*

0.003

1.369

(1.041,1.801)*

0.018

1.478

(1.278,1.708)*

0.003

1.443

(1.270,1.639)

0.070

1.329

(1.116,1.582)*

0.002

HB

1.884

(1.212,2.930)*

0.037

1.446

(1.247,1.678)

0.255

1.637

(1.219,2.198)

0.058

1.414

(1.191,1.678)

0.215

1.333

(1.213,1.465)

0.069

Cancer type

CLL

2.424

(1.995,2.945)

0.841

1.752

(1.466,2.093)

0.825

1.982

(1.674,2.346)

0.968

1.646

(1.431,1.892)

0.445

1.543

(1.407,1.692)

0.647

Lymphoma

1.396

(1.123,1.735)

0.614

1.279

(1.103,1.483)

0.472

1.308

(1.135,1.507)

0.579

1.245

(1.039,1.491)

0.754

1.206

(1.095,1.328)

0.764

Ethnicity

Caucasian

1.844

(1.377,2.470)*

0.003

1.418

(1.124,1.787)*

0.019

1.567

(1.214,2.023)*

0.003

1.463

(1.311,1.633)

0.115

1.350

(1.174,1.554)*

0.003

Asian

1.451

(1.072,1.965)

0.075

1.380

(1.164,1.636)

0.205

1.390

(1.180,1.637)

0.109

1.233

(0.924,1.646)

0.167

1.256

(1.110,1.420)

0.071

  1. PB: population based; HB: hospital based; Bold data represent the positive results.
  2. *Random-effects model was used when P value for heterogeneity test < 0.05; otherwise, fix-effects model was used.
  3. aP value of Q-test for heterogeneity test; BCC: Basal cell carcinoma; SCC: Squamous cell carcinoma; HL: Hodgkin lymphoma; NHL: Non-Hodgkin lymphoma; MM: Multiple myeloma; CLL: Chronic lymphocytic leukaemia.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us